Altered circulating concentrations of active glucagon-like peptide (GLP-1) and dipeptidyl peptidase 4 (DPP4) in obese subjects and their association with insulin resistance

Clinical Biochemistry

Volumn 50, Issue 13-14, 2017, Pages 746-749

  Ahmed, Radwan H ^a   Huri, Hasniza Zaman ^a,b   Muniandy, Sekaran ^c   Al Hamodi, Zaid ^d   Al absi, Boshra ^a   Alsalahi, Abdulsamad ^a   Razif, Muhammad FM ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

^c MAHSA Universi ty   (Malaysia)

^d SANA A UNIVERSITY   (Yemen)

Author keywords

Dipeptidyl peptidase 4; GLP 1; Insulin resistance; Obesity; sDPP4

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; BIOLOGICAL MARKER; DPP4 PROTEIN, HUMAN;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DIET RESTRICTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALAYSIAN; MALE; METABOLIC PARAMETERS; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; AGED; BLOOD; CHEMISTRY; DOWN REGULATION; ETHNOLOGY; MALAYSIA; METABOLISM; MIDDLE AGED; OVERWEIGHT; RISK; SOLUBILITY; STATISTICAL MODEL; UPREGULATION;

ADULT; AGED; BIOMARKERS; BODY MASS INDEX; DIPEPTIDYL PEPTIDASE 4; DOWN-REGULATION; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN RESISTANCE; LINEAR MODELS; MALAYSIA; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; RISK; SOLUBILITY; THINNESS; UP-REGULATION;

EID: 85015399574     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2017.03.008     Document Type: Article

References (37)

1. Finucane, M., Stevens, G., Cowan, M., Danaei, G., Lin, J., Paciorek, C., Singh, G., Gutierrez, H., Lu, Y., Bahalim, A., Global burden of metabolic risk factors of chronic diseases collaborating group (body mass index) national, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 377:9765 (2011), 557–567.
2. WHO, Obesity and Overweight Factsheet From the WHO. Retrieved on May 19 from http://www.who.int/mediacentre/factsheets/fs311/en/; World (2015).
3. Ng, M., Fleming, T., Robinson, M., Thomson, B., Graetz, N., Margono, C., Mullany, E.C., Biryukov, S., Abbafati, C., Abera, S.F., Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the global burden of disease study 2013. Lancet 384:9945 (2014), 766–781.
4. Laakso, M., Kuusisto, J., Insulin resistance and hyperglycaemia in cardiovascular disease development. Nat. Rev. Endocrinol. 10:5 (2014), 293–302.
5. Westphal, S.A., Obesity, abdominal obesity, and insulin resistance. Clin. Cornerstone 9:1 (2008), 23–31.
6. Röhrborn, D., Wronkowitz, N., Eckel, J., DPP4 in diabetes. Front. Immunol., 6, 2015, 386.
7. Zilleßen, P., Celner, J., Kretschmann, A., Pfeifer, A., Racké, K., Mayer, P., Metabolic role of dipeptidyl peptidase 4 (DPP4) in primary human (pre) adipocytes. Sci. Rep., 6, 2016.
8. Cordero, O.J., Salgado, F.J., Nogueira, M., On the origin of serum CD26 and its altered concentration in cancer patients. Cancer Immunol. Immunother. 58:11 (2009), 1723–1747.
9. Zhong, J., Maiseyeu, A., Davis, S.N., Rajagopalan, S., DPP4 in cardiometabolic disease recent insights from the laboratory and clinical trials of DPP4 inhibition. Circ. Res. 116:8 (2015), 1491–1504.
10. Yang, F., Zheng, T., Gao, Y., Baskota, A., Chen, T., Ran, X., Tian, H., Increased plasma DPP4 activity is an independent predictor of the onset of metabolic syndrome in Chinese over 4 years: result from the China National Diabetes and Metabolic Disorders Study. PLoS One, 9(3), 2014.
11. Chen, X.W., He, Z.X., Zhou, Z.W., Yang, T., Zhang, X., Yang, Y.X., Duan, W., Zhou, S.F., Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. Clin. Exp. Pharmacol. Physiol. 42:10 (2015), 999–1024.
12. Baggio, L.L., Drucker, D.J., Biology of incretins: GLP-1 and GIP. Gastroenterology 132:6 (2007), 2131–2157.
13. Cho, Y.M., Fujita, Y., Kieffer, T.J., Glucagon-like peptide-1: glucose homeostasis and beyond. Annu. Rev. Physiol. 76 (2014), 535–559.
14. Holst, J.J., The physiology of glucagon-like peptide 1. Physiol. Rev. 87:4 (2007), 1409–1439.
15. Madsbad, S., The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications. Diabetes. Obes. Metab. 16:1 (2014), 9–21.
16. Lastya, A., Saraswati, M.R., Suastika, K., The low level of glucagon-like peptide-1 (glp-1) is a risk factor of type 2 diabetes mellitus. BMC Res. Notes, 7(1), 2014, 849.
17. WHO, E.C., Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet, 363(9403), 2004, 157.
18. Ismail, I.S., Bebakar, W., Kamaruddin, N., Clinical Practice Guidelines on Management of Obesity 2004, Putrajaya: Ministry of Health Malaysia, Academy of Medicine of Malaysia, Malaysian Association for the Study of Obesity, Malaysian Endocrine and Metabolic Society. 2004, 2004.
19. Friedewald, W.T., Levy, R.I., Fredrickson, D.S., Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18:6 (1972), 499–502.
20. Stengel, A., Goebel-Stengel, M., Teuffel, P., Hofmann, T., Busse, P., Kobelt, P., Rose, M., Klapp, B.F., Obese patients have higher circulating protein levels of dipeptidyl peptidase IV. Peptides 61 (2014), 75–82.
21. Kirino, Y., Sei, M., Kawazoe, K., Minakuchi, K., Sato, Y., Plasma dipeptidyl peptidase 4 activity correlates with body mass index and the plasma adiponectin concentration in healthy young people. Endocr. J. 59:10 (2012), 949–953.
22. Sell, H., Blüher, M., Klöting, N., Schlich, R., Willems, M., Ruppe, F., Knoefel, W.T., Dietrich, A., Fielding, B.A., Arner, P., Adipose dipeptidyl peptidase-4 and obesity correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro. Diabetes Care 36:12 (2013), 4083–4090.
23. Röhrborn, D., Wronkowitz, N., Eckel, J., DPP4 in diabetes. Front. Immunol., 6, 2015.
24. Ding, Y., Li, S., Ma, R.-L., Guo, H., Zhang, J., Zhang, M., Liu, J., Guo, S., Association of homeostasis model assessment of insulin resistance, adiponectin, and low-grade inflammation with the course of the metabolic syndrome. Clin. Biochem. 48:7 (2015), 503–507.
25. Meshkani, R., Adeli, K., Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clin. Biochem. 42:13 (2009), 1331–1346.
26. Ohnuma, K., Takahashi, N., Yamochi, T., Hosono, O., Dang, N.H., Morimoto, C., Role of CD26/dipeptidyl peptidase IV in human T cell activation and function. Front. Biosci., 13(2), 2008, 299.
27. Chielle, E.O., de Souza, W.M., da Silva, T.P., Moresco, R.N., Moretto, M.B., Adipocytokines, inflammatory and oxidative stress markers of clinical relevance altered in young overweight/obese subjects. Clin. Biochem. 49:7–8 (2016), 548–553.
28. Zhong, J., Rao, X., Deiuliis, J., Braunstein, Z., Narula, V., Hazey, J., Mikami, D., Needleman, B., Satoskar, A.R., Rajagopalan, S., A potential role for dendritic cell/macrophage-expressing DPP4 in obesity-induced visceral inflammation. Diabetes 62:1 (2013), 149–157.
29. Ahmed, R.H., Huri, H.Z., Al-Hamodi, Z., Salem, S.D., Muniandy, S., Serum levels of soluble CD26/dipeptidyl peptidase-IV in type 2 diabetes mellitus and its association with metabolic syndrome and therapy with antidiabetic agents in Malaysian subjects. PLoS One, 10(10), 2015, e0140618.
30. Blaslov, K., Bulum, T., Knežević-Ćuća, J., Duvnjak, L., Fasting serum dipeptidyl peptidase-4 activity is independently associated with alanine aminotransferase in type 1 diabetic patients. Clin. Biochem. 48:1 (2015), 39–43.
31. Pala, L., Rotella, C., The role of DPP4 activity in cardiovascular districts: in vivo and in vitro evidence. Journal of Diabetes Research 2013, 2013.
32. Hussein, M.S., Abushady, M.M., Refaat, S., Ibrahim, R., Plasma level of glucagon-like peptide 1 in obese Egyptians with normal and impaired glucose tolerance. Arch. Med. Res. 45:1 (2014), 58–62.
33. Wadden, D., Cahill, F., Amini, P., Randell, E., Vasdev, S., Yi, Y., Church, J., Sun, G., Circulating glucagon-like peptide-1 increases in response to short-term overfeeding in men. Nutr. Metab. (Lond.), 10(1), 2013, 1.
34. Verdich, C., Flint, A., Gutzwiller, J.-P., Naslund, E., Beglinger, C., Hellstrom, P., Long, S., Morgan, L., Holst, J., Astrup, A., A meta-analysis of the effect of glucagon-like peptide-1 (7–36) amide on ad libitum energy intake in humans. The Journal of Clinical Endocrinology & Metabolism 86:9 (2001), 4382–4389.
35. Carr, R.D., Larsen, M.O., Jelic, K., Lindgren, O., Vikman, J., Holst, J.J., Deacon, C.F., Ahrén, B., Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men. The Journal of Clinical Endocrinology & Metabolism 95:2 (2010), 872–878.
36. Rask, E., Olsson, T., Söderberg, S., Johnson, O., Seckl, J., Holst, J.J., Ahrén, B., Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care 24:9 (2001), 1640–1645.
37. Freeman, J.S., Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus. Cleve. Clin. J. Med. 76:Suppl. 5 (2009), S12–S19.